Medtronic is an American Irish-domiciled medical device company headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, Minnesota. Founded in 1949, Medtronic is the world's largest medical device company and a pioneer in deep brain stimulation (DBS) for movement disorders including Parkinson's disease and essential tremor.
| Attribute |
Details |
| Ticker |
NYSE: MDT |
| Headquarters |
Dublin, Ireland (operational: Minneapolis, MN) |
| Founded |
1949 |
| CEO |
Geoff Martha (since 2020) |
| Employees |
~95,000 |
| Market Cap |
~$110 billion (2024) |
| Revenue |
~$32 billion (FY2024) |
Medtronic's primary DBS product line is the Activa family:
- Description: Primary cell-based neurostimulator
- Electrode Contacts: 4 contacts (Medtronic 3387/3389 leads)
- Programming: Standard programming with directional capability via certain leads
- Battery: Rechargeable (typical life: 5-15 years)
- Description: Rechargeable neurostimulator
- Advantages: Smaller size, longer battery life (up to 15 years)
- Charging: Patient-controlled inductive charging
- Description: Most advanced DBS system with sensing capabilities
- Brain Sensing: Can record local field potentials (LFP)
- Closed-Loop: Adaptive DBS capabilities (research use)
Medtronic offers multiple lead configurations:
- 3387: 4-contact, 1.5mm spacing, 10.5mm contact length
- 3389: 4-contact, 0.5mm spacing, 1.5mm contact length (for precise targeting)
- 3391: Directional lead with 8 contacts (3 directional segments)
Medtronic DBS is the most extensively studied treatment for Parkinson's disease motor symptoms:
EARLYSTIM Trial
- Finding: DBS + medical therapy superior to medical therapy alone in patients with early motor complications
- Result: 26% improvement in quality of life (PDQ-39) vs. -1% in control
- Published: Schuepbach et al., NEJM 2013
VA Cooperative Study
- Finding: DBS + medical therapy superior to medical therapy alone
- Result: 41% improvement in off medication motor scores vs. baseline
- Published: Weaver et al., JAMA 2009
Medtronic DBS is FDA-approved for essential tremor:
- Target: Vim nucleus of the thalamus
- Outcome: 50-80% reduction in tremor amplitude
- Published: Ondo et al., Neurology 2006
DBS is approved for dystonia, with significant improvements in:
- Motor function
- Pain reduction
- Quality of life
Medtronic is investigating DBS for:
- Epilepsy: Responsive neurostimulation (separate NeuroPace product)
- Depression: Major depressive disorder (clinical trials)
- Obsessive-Compulsive Disorder: OCD (humanitarian device exemption)
¶ Competitive Landscape
Medtronic competes in the DBS market with:
| Company |
Product |
FDA Status |
Key Features |
| Abbott Laboratories |
Infinity DBS |
Approved (2016) |
Directional leads, small IPG |
| Boston Scientific |
Vercise DBS |
Approved (2017) |
AI navigation, multiple current sources |
Medtronic maintains the largest market share in DBS (>60%).
| Year |
Event |
| 1997 |
FDA approves Medtronic DBS for essential tremor |
| 2002 |
FDA approves DBS for Parkinson's disease |
| 2015 |
FDA approves Activa PC + S for Parkinson's, dystonia, epilepsy |
| 2018 |
FDA approves directional leads |
| 2023 |
FDA approves Percept PC with brain sensing |
- Patients Treated: >150,000 patients worldwide since 1997
- Implant Centers: Thousands of hospitals globally
- Clinical Publications: 2,000+ peer-reviewed papers on Medtronic DBS
¶ Research and Development
- Adaptive DBS: Closed-loop systems that adjust stimulation based on neural signals
- Directional Leads: Improved targeting to reduce side effects
- Sensing Capabilities: Brain signal recording for personalized programming
- MR Conditional: Full-body MRI compatibility
Medtronic collaborates with:
- Academic medical centers
- Neuroscience research institutions
- Other medical device companies
- Abbott Laboratories - Competitor (Infinity DBS)
- Boston Scientific - Competitor (Vercise DBS)
- NeuroPace - Related (RNS for epilepsy)
- Subthalamic Nucleus
- Thalamus
- Globus Pallidus